<!DOCTYPE html>
<html lang="en">
<head>
  <meta charset="UTF-8">
  <meta name="viewport" content="width=device-width, initial-scale=1.0">
  <title>Pubmed Article Illustration #1</title>
  <link rel="stylesheet" type="text/css" href="styles.css">
  <script src="https://cdn.jsdelivr.net/npm/chart.js"></script>
  <script src="https://cdn.jsdelivr.net/npm/chartjs-plugin-datalabels"></script>
  <script src="https://unpkg.com/@chartjs/chartjs-chart-error-bars"></script>
</head>
<body>
<div class="header">
  <h1>In Vivo Effects of Goldenseal, Kava Kava, Black Cohosh, and Valerian on Human Cytochrome P450 1A2, 2D6, 2E1, and 3A4/5 Phenotypes</h1>
</div>
  <p>Gurley BJ, Gardner SF, Hubbard MA, Williams DK, Gentry WB, Khan IA, Shah A</p>
  <p>Department of Pharmaceutical Sciences, College of Pharmacy, University of Arkansas for Medical Sciences, Little Rock, Arkansas, USA</p>
  <div class="toolbar">
    <div class="dropdown">
      <button class="dropbtn">Citation</button>
      <div class="dropdown-content">
        <p>Gurley BJ, Gardner SF, Hubbard MA, Williams DK, Gentry WB, Khan IA, Shah A. In vivo effects of goldenseal, kava kava, black cohosh, and valerian on human cytochrome P450 1A2, 2D6, 2E1, and 3A4/5 phenotypes. Clin Pharmacol Ther. 2005 May;77(5):415-26. doi: 10.1016/j.clpt.2005.01.009. PMID: 15900287; PMCID: PMC1894911.</p>
      </div>
    </div>
    <a href="https://www.pharmgkb.org/"><button title="Pharmgkb">Genomic Information</button></a>
    <a href="https://pk-db.com/data?tab=studies"><button title="PK-DB Database">PK Information</button></a>
    <a href="https://pubmed.ncbi.nlm.nih.gov/15900287/"><button title="PubMed Article">Pubmed</button></a>
    <a href="https://naturalmedicines.therapeuticresearch.com/"><button title="Herb-Medication Database">NatMed Pro</button></a>
    <a href="https://go.drugbank.com/"><button title="Drug-Database">DrugBank</button></a>
  </div>
  </div>
  <div id="centeredContainer">
    <div id="objectivesContainer"></div>
    <div id="methodsContainer"></div>
    <div id="resultsContainer"></div>
    <div id="selectContainer">
      <div id="enzymeGrid" class="selector"></div>
      <div id="herbGrid" class="selector"></div>
      <button id="goBack" style="display: none;">Go Back</button>
      <div id="interactionDisplay"></div>
    </div>
    <div class="chart-container">
      <canvas id="interactionChart"></canvas>
    </div>
    <div id="conclusionsContainer"></div>
    <div id="referencesContainer">
      <h2>References</h2>
        <ol>
          <li>Izzo AA, Ernst E. Interactions between herbal medicines and prescribed drugs: A systematic review. Drugs. 2001;61:2163–2175. - PubMed</li>
          <li>Ang-Lee MK, Moss J, Yuan C. Herbal medicines and perioperative care. JAMA. 2001;286:208–216. - PubMed</li>
          <li>Brazier NC, Levine MAH. Drug-herb interaction among commonly used conventional medicines: a compendium for health care professionals. Am J Ther. 2003;10:163–169. - PubMed</li>
          <li>Gurley BJ, Hagan DW. Herbal and dietary supplement interactions with drugs. In: McCabe BJ, Frankel EH, Wolfe JJ, editors. Handbook of Food-Drug Interactions. Boca Raton: CRC Press; 2003. pp. 259–293.</li>
          <li>Barone GW, Gurley BJ, Ketel BL, Abul-Ezz SR. Herbal dietary supplements: a source for drug interactions in transplant recipients. Transplantation. 2001;71:239–241. - PubMed</li>
          <li>Piscitelli SC, Burstein AH, Chaitt D, Alfaro RM, Falloon J. Indinavir concentrations and St John’s wort. Lancet. 2000;355:547–548. - PubMed</li>
          <li>Wang Z, Gorski JC, Hamman MA, Huang S, Lesko LJ, Hall SD. The effects of St. John’s wort (Hypericum perforatum) on human cytochrome P450 activity. Clin Pharmacol Ther. 2001;70:317–326. - PubMed</li>
          <li>Sugimoto K, Ohmori M, Tsuruoka S, et al. Different effects of St. John’s wort on the pharmacokinetics of simvastatin and pravastatin. Clin Pharmacol Ther. 2001;70:518–524. - PubMed</li>
          <li>Mathijssen RHJ, Verweij J, de Bruijn P, Loos WJ, Sparreboom A. Effects of St John’s wort on irinotecan metabolism. J Nat Cancer Inst. 2002;94:1247–1249. - PubMed</li>
          <li>Hall SD, Wang Z, Huang S-M, Hamman MA, Vasavada N, Adigun AQ, Hilligoss JK, Miller M, Gorski JC. The interaction between St John’s wort and an oral contraceptive. Clin Pharmacol Ther. 2003;74:525–535. - PubMed</li>
          <li>Moore LB, Goodwin B, Jones SA, et al. St. John’s wort induces hepatic drug metabolism through activation of the pregnane X receptor. Proc Nat Acad Sci. 2000;97:7500–7502. - PMC - PubMed</li>
          <li>Budzinski JW, Foster BC, Vandenhoek S, Arnason JT. An in vitro evaluation of human cytochrome P450 3A4 inhibition by selected commercial herbal extracts and tinctures. Phytomed. 2000;7:273–282. - PubMed</li>
          <li>Zou L, Harkey MR, Henderson GL. Effects of herbal components on cDNA-expressed cytochrome P450 enzyme catalytic activity. Life Sci. 2002;71:1579–1589. - PubMed</li>
          <li>Foster BC, Vandenhoek S, Hana J, Krantis A, Akhtar MH, Bryan M, Budzinski JW, Ramputh A, Arnason JT. In vitro inhibition of human cytochrome P450-mediated metabolism of marker substrates by natural products. Phytomed. 2003;10:334–342. - PubMed</li>
          <li>Raucy JL. Regulation of CYP3A4 expression in human hepatocytes by pharmaceuticals and natural products. Drug Metab Dispos. 2003;31:533–539. - PubMed</li>
          <li>Strandell J, Neil A, Carlin G. An approach to the in vitro evaluation of potential for cytochrome P450 enzyme inhibition from herbals and other natural remedies. Phytomed. 2004;11:98–104. - PubMed</li>
          <li>Foster BC, Foster MS, Vandenhoek S, Krantis A, Budzinski JW, Arnason JT, Gallicano KD, Choudri S. An in vitro evaluation of human cytochrome P450 3A4 and P-glycoprotein inhibition by garlic. J Pharm Pharmaceut Sci. 2001;4:176–184. - PubMed</li>
          <li>Unger M, Holzgrabe U, Jacobsen W, Cummins C, Benet LZ. Inhibition of cytochrome P450 3A4 by extracts and kavalactones of Piper methysticum (Kava kava) Planta Med. 2002;68:1055–1058. - PubMed</li>
          <li>Matthews JM, Etheridge AS, Black SR. Inhibition of human cytochrome P450 activities by kava extract and kava lactones. Drug Metab Dispos. 2002;30:1153–1157. - PubMed</li>
          <li>Chatterjee P, Franklin MR. Human cytochrome P450 inhibition and metabolic-intermediate complex formation by goldenseal extract and its methylenedioxyphenyl components. Drug Metab Dispos. 2003;31:1391–1397. - PubMed</li>
          <li>Zou L, Henderson GL, Harkey MR, Sakai Y, Li A. Effects of Kava (Kava-kava, ‘Awa, Yaqona, Piper methysticum) on c-DNA-expressed cytochrome P450 enzymes and human cryopreserved hepatocytes - PubMed</li>
          <li>Henderson GL, Harkey MR, Gershwin ME, Hackman RM, Stern JS, Stresser DM. Effects of ginseng components on c-DNA-expressed cytochrome P450 enzyme catalytic activity - PubMed</li>
          <li>Gorski JC, Huang S-M, Pinto A, Hamman MA, Hilligoss JK, Zaheer NA, Desai M, Miller M, Hall SD. The effect of Echinacea (Echinacea purpurea root) on cytochrome P450 activity in vivo. Clin Pharmacol Ther. 2004;75:89–100. - PubMed</li>
          <li>Gurley BJ, Gardner SF, Hubbard MA, Williams K, Gentry B, Carrier J, Khan I, Edwards D, Shah A. In vivo assessment of botanical supplementation on human cytochrome P450 phenotypes: Citrus aurantium, Echinacea purpurea, milk thistle, and saw palmetto. Clin Pharmacol Ther. 2004;76:428–440. - PubMed</li>
          <li>Markowitz JS, Donovan JL, DeVane CL, Taylor RM, Ruan Y, Wang J-S, Chavin KD. Multiple doses of saw palmetto (Serenoa repens) did not alter cytochrome P450 2D6 and 3A4 activity in normal volunteers. Clin Pharmacol Ther. 2003;74:536–542. - PubMed</li>
          <li>Gurley BJ, Gardner SF, Hubbard MA, Williams DK, Gentry WB, Cui Y, Ang CYW. Cytochrome P450 phenotypic ratios for predicting herb-drug interactions in humans. Clin Pharmacol Ther. 2002;72:276–282. - PubMed</li>
          <li>Anderson GD, Rosito G, Mohustsy MA, Elmer GW. Drug interaction potential of soy extract and Panax ginseng. J Clin Pharmacol. 2003;43:643–648. - PubMed</li>
          <li>Sridar C, Goosen TC, Kent UM, Williams JA, Hollenberg PF. Silybin inactivates cytochromes P450 3A4 and 2C9 and inhibits major hepatic glucuronosyltransferases. Drug Metab Dispos. 2004;32:587–594. - PubMed</li>
          <li>Venkataramanan R, Ramachandran V, Komoroski BJ, Zhang S, Schiff PL, Strom SC. Milk thistle, a herbal supplement, decreases the activity of CYP3A4 and uridine diphosphoglucuronsyl transferse in human hepatocyte cultures. Drug Metab Dispos. 2000;28:1270–1273. - PubMed</li>
          <li>Markowitz JS, Donovan JL, DeVane CL, Sipkes L, Chavin KD. Multiple-dose administration of Ginkgo biloba did not affect cytochrome P-450 2D6 or 3A4 activity in normal volunteers. J Clin Psychopharmacol. 2003;23:576–581. - PubMed</li>
          <li>Piscitelli SC, Burstein AH, Welden N, Gallicano KD, Falloon J. The effect of garlic supplements on the pharmacokinetics of saquinavir. Clin Infect Dis. 2002;34:234–238. - PubMed</li>
          <li>Markowitz JS, DeVane CL, Chavin KD, Taylor RM, Ruan Y, Donovan JL. Effects of garlic (Allium sativum L.) supplementation on cytochrome P450 2D6 and 3A4 activity in healthy volunteers. Clin Pharmacol Ther. 2003;74:170–177. - PubMed</li>
          <li>Donovan JL, DeVane CL, Chavin KD, Wang J-S, Gibson BB, Gefroh HA, Markowitz JS. Multiple nighttime doses of valerian (Valeriana officinalis) had minimal effects on CYP3A4 activity and no effect on CYP2D6 activity in healthy volunteers. Drug Metab Dispos. 2004;32:1333–1336. - PubMed</li>
          <li>Cote CS, Kor C, Cohen J, Auclair K. Composition and biological activity of traditional and commercial kava extracts. Biochem Biophys Res Comm. 2004;322:147–152. - PubMed</li>
          <li>Lefebvre T, Foster BC. In vitro activity of commercial valerian root extracts against human cytochrome P450 3A4. J Pharm Pharmaceut Sci. 2004;7:265–273. - PubMed</li>
          <li>Russman S, Helbling A. Kava hepatoxicity. Ann Int Med. 2001;135:68–69. - PubMed</li>
          <li>Whitton PA, Lau A, Salisbury A, Whitehouse J, Evans CS. Kava lactones and the kava-kava controversy. Phytochemistry. 2003;64:673–679. - PubMed</li>
          <li>Clough AR, Bailie RS, Currie B. Liver function test abnormalities in users of aqueous kava extracts. J Toxicol Clin Toxicol. 2003;41:821–829. - PubMed</li>
          <li>Palmer JL, Scott RJ, Gibson A, Dickins M, Pleasance S. An interaction between cytochrome P450 probe substrates chlorzoxazone (CYP2E1) and midazolam (CYP3A). Br J Clin Pharmacol. 2001;52:555–561. - PMC - PubMed</li>
          <li>Holland DT, Godfredsen KA, Page T, Connor JD. Simple high performance liquid chromatography method for the simultaneous determination of serum caffeine and paraxanthine following rapid sample preparation. J Chromatogr (B) 1998;707:105–110. - PubMed</li>
          <li>Frye RF, Stiff DD. Determination of chlorzoxazone and 6-hydroxychlorzoxazone in human plasma and urine by high-performance liquid chromatography. J Chromatogr (B) 1996;686:291–296. - PubMed</li>
          <li>Frye RF, Branch RA. Improved high-performance liquid chromatographic determination of debrisoquine and 4-hydroxydebrisoquin in human urine following direct injection. J Chromatogr (B) 1996;677:178–182. - PubMed</li>
          <li>Sautou V, Chopineau J, Terrisse MP, Bastide P. Solid-phase extraction of midazolam and two of its metabolites from plasma for high performance liquid chromatographic analysis. J Chromatogr (B) 1991;571:298–304. - PubMed</li>
          <li>Abourashed EA, Khan IA. High-performance liquid chromatography determination of hydrastine and berberine in dietary supplements containing goldenseal. J Pharm Sci. 2001;90:817–822. - PubMed</li>
          <li>Ganzera M, Khan IA. Analytical techniques for the determination of lactones in Piper methysticum Forst. Chromatographia. 1999;50:649–653.</li>
          <li>Ganzera M, Bedir E, Khan IA. Separation of Cimicifuga racemosa triterpene glycosides by evaporative light scattering detection. Chromatographia. 2000;52:301–304.</li>
          <li>Mikell JR, Ganzera M, Khan IA. Analysis of sesquiterpenes in Valeriana officinalis by capillary electrophoresis. Pharmazie. 2001;56:946–948. - PubMed</li>
          <li>The Pharmacopeia of the United States Twenty-seventh Revision, and the National Formulary. 22. Rockville: United States Pharmacopeial Convention, Inc.; 2004. Disintegration and dissolution of dietary supplements; pp. 2645–2646.</li>
          <li>Cohen J. Statistical Power Analysis for the Behavioral Sciences. 2. Lawrence Erlbaum Associates Publishers; 1988. pp. 19–42.</li>
          <li>Chatterjee P, Franklin MR. Human cytochrome P450 inhibition and metabolic-intermediate complex formation by goldenseal extract and its methylenedioxyphenyl components. Drug Metab Dispos. 2003;31:1391–1397. - PubMed</li>
          <li>Bhide MB, Chavan SR, Dutta NK. Absorption, distribution and excretion of berberine. Ind J Med Res. 1969;57:2128–2131. - PubMed</li>
          <li>Pan G, Wang G-J, Liu X-D, Fawcett JP, Xie Y-Y. The involvement of p-glycoprotein in berberine absorption. Pharmacol Toxicol. 2002;91:193–197. - PubMed</li>
          <li>Sandhu RS, Prescilla RP, Simonelli TM, Edwards DJ. Influence of goldenseal root on the pharmacokinetics of indinavir. J Clin Pharmacol. 2003;43:1283–1288. - PubMed</li>
          <li>Shao Y, Harris A, Wang M, Zhang H, Cordell Bowman, Lemmo E. Triterpene glycosides from Cimicifuga racemosa. J Nat Prod. 2000;63:905–910. - PubMed</li>
          <li>Li W, Sun Y, Liang W, Fitzloff JF, van Breemen RB. Identification of caffeic acid derivatives in Aceta racemosa (Cimicifuga racemosa, black cohosh) by liquid chromatography/tandem mass spectrometry. Rapid Comm Mass Spectrom. 2003;17:978–982. - PubMed</li>
          <li>Johnson BM, van Breemen RB. In vitro formation of quinoid metabolites of the dietary supplement Cimicifuga racemosa (Black cohosh) Chem Res Toxicol. 2003;16:838–846. - PubMed</li>
          <li>Huntley A, Ernst E. A systematic review of the safety of black cohosh. Menopause. 2003;10:58–64. - PubMed</li>
          <li>Borrelli F, Izzo AA, Ernst E. Pharmacological effects of Cimicifuga racemosa. Life Sci. 2003;73:1215–1229. - PubMed</li>
          <li>Teschke R, Gaus W, Loew D. Kava extracts: safety and risks including rare hepatoxicity. Phytomedicine. 2003;10:440–446. - PubMed</li>
          <li>Clouatre DL. Kava kava: examining new reports of toxicity. Toxicol Lett. 2004;150:85–96. - PubMed</li>
          <li>Food and Drug Administration. Letter to health-care professionals: FDA issues consumer advisory that kava products may be associated with severe liver injury. Vol. 36. US Department of Health and Human Services; Rockville, MD: May/June, 2002. p. 4. Available at http://www.cfsan.fda.gov/~dms/addskava.html.</li>
          <li>Avdeef A, Strafford M, Block E, Balogh MP, Chambliss W, Khan I. Drug absorption in vitro model: filter-immobilized artificial membranes 2. Studies of the permeability properties of lactones in Piper methysticum Forst. Eur J Pharm Sci. 2001;14:271–280. - PubMed</li>
          <li>Shohet D, Wills RBH, Stuart DL. Valepotriates and valerenic acid in commercial preparations of valerian available in Australia. Pharmazie. 2001;56:860–863. - PubMed</li>
        </ol>
      </div>
    <div id="Appendix">
      <h2>Appendix</h2>
      <p>Content of phytochemical marker compounds, dosage form, and disintegration times for botanical supplements.</p>
    </div>
    <div id="footnoteDisplay"></div>
    <footer>
      <p>Clinical Pharmacology & Therapeutics, 2005</p>
    </footer>
    <script src="js/app.js"></script>
  </div>
</body>
</html>